Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Biofrontera's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Biofrontera's regulatory disclosures and financial reporting.
Amendment No. 3 to Schedule 13D shows that Biofrontera AG ("BFAG") and related German investment vehicles—Deutsche Balaton AG, VV Beteiligungen AG, Delphi Unternehmensberatung AG—and six individuals now collectively control 458,884 Biofrontera Inc. shares, or 4.86 % of the 9,446,197 shares outstanding. BFAG itself holds 400,000 shares (4.23 %). Dilution from successive equity issuances and a 1-for-20 reverse split pushed each filer below the 5 % reporting threshold.
Key new element: on 30 Jun 2025 BFAG transferred all U.S. rights to Ameluz and RhodoLED back to the issuer. In return BFAG received (i) a 12 – 15 % royalty on future U.S. Ameluz sales (rate rises above US$65 m revenue) and (ii) 3,019 shares of Series D Convertible Preferred Stock. Each preferred share converts into common at US$0.6249, equating to 4,831,172 common shares. Conversion and associated voting rights are blocked until shareholder approval.
If conversion is approved, BFAG’s stake would jump to roughly 51 % of current shares outstanding, restoring majority control and giving BFAG the right to appoint up to two directors for three years. Deutsche Balaton indicates it may buy or sell additional shares depending on market conditions; the other reporting persons currently have no direct purchase plans. No criminal or civil proceedings involve the filers, though DB has ongoing German litigation against BFAG concerning the 2021 IPO.